«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

28卷

期数:

2022年05期

页码:

497-502

栏目:

基础医学

出版日期:

2022-09-20

文章信息/Info

Title:

CD155-dependent m6A modification regulates malignant behavior of cervical cancer cells

文章编号:

1006-8147(2022)05-0497-06

作者:

祁小珍石立莹

（天津医科大学基础医学院病原生物学教研室 天津 300070 ）

Author(s):

QI Xiao-zhen; SHI Li-ying

（Department of Pathogen Biology，School of Basic Medical Sciences，Tianjin Medical University，Tianjin 300070，China）

关键词:

CD155; 宫颈癌; m6A; METTL3; YTHDF1

Keywords:

CD155; cervical cancer; m6A; METTL3; YTHDF1

分类号:

R737.33

DOI:

-

文献标志码:

A

摘要:

目的：探究CD155在宫颈癌中的作用和依赖m6A修饰的调控机制。方法：应用数据库预测宫颈癌细胞中CD155（PVR）的表达情况，CD155对患者预后的影响，运用实时荧光定量PCR（qRT-PCR）法测定宫颈癌细胞HeLa和宫颈永生细胞S12中CD155的表达水平。分别运用MTT、平板克隆、迁移侵袭等实验评估CD155对宫颈癌细胞HeLa生长、增殖、迁移和侵袭的影响。应用Western印迹法测定E-钙黏蛋白（E-cad）和波形蛋白（Vimentin）的表达水平并评价CD155对EMT的影响。MeRIP-RT-qPCR检测CD155是否受m6A 调控，Western印迹法和qRT-PCR测定METTL3是否影响CD155蛋白和RNA的表达水平。放线菌素D处理细胞后检测METTL3对CD155RNA半衰期的作用，利用预测网站m6ATaget预测CD155RNA甲基化位点的识别者（Reader），运用Western印迹法和qRT-PCR分析YTHDF1是否影响CD155蛋白和RNA的表达水平，放线菌素D处理细胞后检测YTHDF1对CD155RNA半衰期的作用，RIP-RT-qPCR实验进一步确定YTHDF1和YTHDF1-mut对CD155RNA下拉能力。结果： CD155在宫颈癌组织和细胞中表达较高，体内高表达CD155的患者生存率较低。相比S12细胞，HeLa细胞中CD155的表达增加（t=3.749，P<0.05）。CD155的高表达促进了体外宫颈癌细胞的生长（t=3.152，P<0.05）、增殖（t=3.706，P<0.05）、迁移（t=5.422，P<0.01）和侵袭（t=3.599，P<0.05），抑制E-cad的表达促进了Vimentin的表达。MeRIP-RT-qPCR结果显示CD155RNA受m6A调控，METTL3促进了CD155蛋白和RNA（t=6.725，P<0.05）的表达，敲降METTL3之后CD155RNA半衰期降低（t=5.622、6.063、5.857，均P<0.05）。敲降YTHDF1之后CD155的蛋白水平降低，CD155RNA半衰期降低（t=10.93、5.602、4.359，均P<0.05）。在YTHDF1高表达的细胞中，CD155RNA被有效免疫沉淀（t=4.686，P<0.01），但在YTHDF1-mut转染的细胞中，免疫沉淀结果显示下拉的CD155RNA水平明显降低（t=4.462，P<0.05）。结论：CD155RNA在m6A修饰的情况下，被YTHDF1特异性识别，进而稳定性增强和翻译增加，CD155表达增加促进了宫颈癌细胞的恶性行为。

Abstract:

Objective： To explore the role of CD155 in cervical cancer and its regulatory mechanism dependent on m6A modification. Methods: The database was used to predict the expression of CD155（PVR） in cervical cancer cells，and the effect of CD155 on the prognosis of patients. The expression levels of CD155 in cervical cancer cells HeLa and cervical immortalized cells S12 were determined by real-time quantitative PCR （qRT-PCR）. The effects of CD155 on the growth，proliferation，migration，and invasion of cervical cancer cells HeLa were evaluated by MTT，plate cloning，migration and invasion experiments. The expression levels of E-cadherin（E-cad） and vimentin（Vimentin） were determined by Western blotting and the effect of CD155 on EMT process was evaluated. MeRIP-RT-qPCR was used to detect whether CD155 was regulated by m6A，and Western blotting and qRT-PCR were used to determine whether METTL3 affected the expression levels of CD155 protein and RNA. Actinomycin D treated cells to detect the effect of METTL3 on the half-life of CD155 RNA，using the prediction website m6ATaget to predict the recognizer（Reader） of CD155 RNA methylation sites，Western blotting and qRT-PCR were used to analyze whether YTHDF1 affects the expression levels of CD155 protein and RNA，Actinomycin D treated cells to detect the effect of YTHDF1 on the half-life of CD155 RNA，and RIP-RT-qPCR experiment further confirmed the pull-down ability of YTHDF1 and YTHDF1-mut on CD155 RNA. Results: CD155 was highly expressed in cervical cancer tissues and cells，and patients with high CD155 expression in vivo had a lower survival rate. Compared with S12 cells，the expression of CD155 was increased in HeLa cells （t=3.749，P<0.05）. High expression of CD155 promoted the growth （t=3.152，P<0.05），proliferation （t=3.706，P<0.05），migration （t=5.422，P<0.01）and invasion （t=3.599，P<0.05） of cervical cancer cells in vitro，inhibited the expression of E-cad and promoted the expression of Vimentin. MeRIP-RT-qPCR results showed that CD155RNA was regulated by m6A，METTL3 promoted the expression of CD155 protein and RNA（t=6.725，P<0.05），and knockdown of METTL3 decreased the half-life of CD155RNA（t=5.622，6.063，5.857，all P<0.05）. After knockdown of YTHDF1，the protein level of CD155 decreased，and the half-life of CD155 RNA decreased（t=10.93，5.602，4.359，all P<0.05）. In cells with high YTHDF1 expression，CD155RNA was efficiently immunoprecipitated（t=4.686，P<0.01），but in YTHDF1-mut transfected cells，the immunoprecipitation results showed that the level of pulled down CD155RNA was significantly reduced（t=4.462，P<0.05）. Conclusion: CD155RNA is specifically recognized by YTHDF1 under the condition of m6A modification，and then the stability and translation are increased，and the increased expression of CD155 promotes the malignant behavior of cervical cancer cells.

参考文献/References:

[1] ARBYN M，WEIDERPASS E，BRUNI L，et al. Estimates of incidence and mortality of cervical cancer in 2018：a worldwide analysis[J]. Lancet Glob Health，2020，8（2）:e191-e203.
[2] HE C. Grand challenge commentary：RNA epigenetics?[J]. Nat Chem Biol，2010，6（12）：863-865.
[3] DENG X，SU R，WENG H，et al. RNA N6-methyladenosine modification in cancers：current status and perspectives[J].Cell Res，2018，28（5）：507-517.
[4] YANG Y，HSU P J，CHEN Y S，et al. Dynamic transcriptomic m6A decoration：writers，erasers，readers and functions in RNA metabolism[J]. Cell Res，2018 ，28（6）：616-624.
[5] XU H，WANG H，ZHAO W，et al. SUMO1 modification of methyltransferase-like 3 promotes tumor progression via regulating Snail mRNA homeostasis in hepatocellular carcinoma[J]. Theranostics，2020，10（13）：5671-5686.
[6] VU L P，PICKERING B F，CHENG Y，et al. The N6-methyladenosine （m6A）-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells[J]. Nat Med，2017，23（11）：1369-1376.
[7] LIN S，CHOE J，DU P，et al. The m（6）A Methyltransferase METTL3 promotes translation in human cancer cells[J]. Mol Cell，2016，62（3）：335-345.
[8] VISVANATHA N A，PATIL V，ARORA A，et al. Essential role of METTL3-mediated m6A modification in glioma stem-like cells maintenance and radioresistance[J]. Oncogene，2018，37（4）：522-533.
[9] HU Y，LI Y，HUANG Y，et al. METTL3 regulates the malignancy of cervical cancer via post-transcriptional regulation of RAB2B[J]. Eur J Pharmacol，2020，879：173134.
[10] DENG X，SU R，WENG H，et al. RNA N6-methyladenosine modification in cancers：current status and perspectives[J].Cell Res，2018，28（5）：507-517.
[11] MASSON D，JARRY A，BAURY B，et al. Overexpression of the CD155 gene in human colorectal carcinoma[J]. Gut，2001，49（2）：236-240.
[12] NAKAI R，MANIWA Y，TANAKA Y，et al.Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma[J]. Cancer Sci，2010，101（5）：1326-1330.
[13] BEVELACQUA V，BEVELACQUA Y，CANDIDO S，et al. Nectin like-5 overexpression correlates with the malignant phenotype in cutaneous melanoma[J]. Oncotarget，2012，3（8）：882-892.
[14] NISHIWADA S，SHO M，YASUDA S，et al. Clinical significance of CD155 expression in human pancreatic cancer[J]. Anticancer Res，2015，35（4）：2287-2297.
[15] DOUGALL W C，KURTULUS S，SMYTH M J，et al. TIGIT and CD96：new checkpoint receptor targets for cancer immunotherapy[J]. Immunol Rev，2017，276（1）：112-120.
[16] LIU L，WANG Y，GENG C，et al. CD155 Promotes the progression of cervical cancer cells through AKT/mTOR and NF-κB pathways[J]. Front Oncol，2021，11：655302.
[17] SUNG H，FERLAY J，SIEGEL R L，et al. Globalcancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2021，71（3）：209-249.
[18] FRIEDLANDER M，GROGAN M U S， Preventative Services Task Force. Guidelines for the treatment of recurrent and metastatic cervical cancer[J]. Oncologist，2002，7（4）：342-347.
[19] VONSKY M，SHABAEVA M，RUNOV A，et al. Carcinogenesis associated with human papillomavirus infection. mechanisms and potential for immunotherapy[J]. Biochemistry（Mosc），2019，84（7）：782-799.
[20] PLUMMER M，PETO J，FRANCESCHI S，et al. Time since first sexual intercourse and the risk of cervical cancer[J]. Int J Cancer，2012，130（11）：2638-2644.
[21] MURAKAMI T，TAKASAWA A，TAKASAWA K，et al. Aberrant expression of junctional adhesion molecule-a contributes to the malignancy of cervical adenocarcinoma by interaction with poliovirus receptor/CD155[J]. Cancer Sci，2021，112（2）：906-917.
[22] O′DONNELL J S，MADORE J，LI X Y，et al. Tumor intrinsic and extrinsic immune functions of CD155[J]. Semin Cancer Biol，2020，65：189-196.

相似文献/References:

[1]李晶晶,赵卫东,王德华.72例宫颈癌术后并发症及卵巢功能分析[J].天津医科大学学报,2014,20(01):63.
[2]崔丽阳,岳天孚.高危型HPV持续感染的影响因素探讨[J].天津医科大学学报,2014,20(03):209.
　CUI Li-yang,YUE Tian-fu.Investigation on factors for persistent high-risk human papilloma virus infection[J].Journal of Tianjin Medical University,2014,20(05):209.
[3]孙 艳,齐 政,王德华,等.miR-186通过靶定CEA抑制宫颈癌细胞转移[J].天津医科大学学报,2016,22(04):288.
　SUN Yan,QI Zheng,WANG De-hua,et al.miR-186 inhibits cervical cancer migration by targetting CEA[J].Journal of Tianjin Medical University,2016,22(05):288.
[4]李 娜,李洪林,尹利荣.HPV E6/E7 mRNA与YAP在宫颈癌中的表达与相关性研究[J].天津医科大学学报,2018,24(04):307.
　LI Na,LI Hong-lin,YIN Li-rong.HPV E6/E7 mRNA and YAP expression and their correlation in cervical carcinoma[J].Journal of Tianjin Medical University,2018,24(05):307.
[5]曲首辉,鲍志敏,刘荣欣.TCT、活检病理在宫颈上皮瘤变及早期宫颈癌诊断中的价值分析[J].天津医科大学学报,2018,24(04):360.
[6]陈 辉,樊茹佳,丁继侠.宫颈癌组织中Foxm1、ANGPTL4蛋白表达及临床意义[J].天津医科大学学报,2019,25(05):510.
　CHEN Hui,FAN Ru-jia,DING Ji-xia.Expression and clinical significance of Foxm1 and ANGPTL4 protein in cervical cancer tissues[J].Journal of Tianjin Medical University,2019,25(05):510.
[7]闫晓芳,谢 虹,汤 华.miR-3685通过靶向CTTN抑制宫颈癌细胞的迁移、侵袭及生长[J].天津医科大学学报,2020,26(01):8.
　YAN Xiao-fang,XIE Hong,TANG Hua.miR-3685 inhibits migration, invasion and growth of cervical cancer cells by targeting CTTN[J].Journal of Tianjin Medical University,2020,26(05):8.
[8]白丽丽,汤华.TNF-α诱导的circMAN1A2促进宫颈癌细胞的迁移、侵袭和增殖[J].天津医科大学学报,2020,26(02):103.
　BAI Li-li,TANG Hua.TNF-α-induced circMAN1A2 promotes migration, invasion and proliferation of cervical cancer cells[J].Journal of Tianjin Medical University,2020,26(05):103.
[9]赵敬,杨金豪,张文帆,等.2009—2020年中国女性生殖道支原体、衣原体和人乳头瘤病毒感染与宫颈癌发生相关性的Meta分析[J].天津医科大学学报,2021,27(04):396.
　ZHAO Jing,YANG Jin-hao,ZHANG Wen-fan,et al.A meta-analysis of association between Mycoplasma，Chlamydia infection and Human papillomavirus infection in female genital tract and cervical cancer in China from 2009 to 2020[J].Journal of Tianjin Medical University,2021,27(05):396.
[10]赵敬,杨金豪 综述,常艳敏,等.中国宫颈癌DNA甲基化标志物的研究进展[J].天津医科大学学报,2021,27(05):545.

备注/Memo

备注/Memo:

作者简介 祁小珍（1993-），女，硕士在读，研究方向：病原生物学；通信作者：石立莹，E-mail：sly.good@126.com。

常用功能

更新日期/Last Update: 2022-09-20